Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Intelligent Bio Solutions ( (INBS) ).
On December 31, 2025, Intelligent Bio Solutions entered into a securities purchase agreement with healthcare-focused institutional investors for a private placement of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof) together with Series K-1 and Series K-2 warrants, at a combined purchase price of $4.35, generating approximately $10.0 million in gross proceeds; the transaction, priced at-the-market under Nasdaq rules, closed on January 2, 2026, with 105,000 shares and 2,193,850 pre-funded warrants issued, taking the company’s outstanding common stock to 1,216,142 shares. The warrants are immediately exercisable, with pre-funded warrants priced at $0.01 per share and Series K-1 and K-2 warrants at $4.10 per share for a five-year term following effectiveness of a registration statement, while the company has committed to register the resale of the shares and warrant shares and plans to use the net proceeds for working capital and general corporate purposes, bolstering its balance sheet and providing additional funding flexibility as it pursues growth in the non-invasive drug testing market; Ladenburg Thalmann acted as exclusive placement agent under a fee and expense arrangement tied to the offering and any future warrant exercises.
The most recent analyst rating on (INBS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Spark’s Take on INBS Stock
According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.
The score is primarily held down by weak financial performance (persistent losses and negative cash flows) and bearish technicals (price below key moving averages with negative MACD). Valuation is constrained by a negative P/E and no dividend, while corporate events are mixed but include elevated listing-risk signals despite customer-account growth.
To see Spark’s full report on INBS stock, click here.
More about Intelligent Bio Solutions
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions. Its flagship product, the Intelligent Fingerprinting Drug Screening System, uses fingerprint sweat analysis to provide hygienic, cost-effective, point-of-care screening for recent drug use, including opiates, cocaine, methamphetamine and cannabis, with results in under ten minutes. The company currently serves customer segments outside the U.S. in safety-critical and compliance-driven sectors such as construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners.
Average Trading Volume: 1,783,758
Technical Sentiment Signal: Sell
Current Market Cap: $9.14M
For a thorough assessment of INBS stock, go to TipRanks’ Stock Analysis page.